McGuire, Alistair 
ORCID: 0000-0002-5367-9841, Fenn, Paul and Gray, Alistair
(1996)
An economic evaluation of universal vaccination against Hepatitis B virus.
Journal of Infection, 32 (3).
pp. 197-204.
ISSN 0163-4453
Abstract
This report presents the results of an economic evaluation utilizing U.K. data, into a vaccination programme against Hepatitis B using a genetically engineered, yeast-derived vaccine, Engerix B. Cost-effectiveness ratios were calculated for four different programmes: an infant vaccination programme; a child vaccination programme; an adolescent vaccination programme; and a combined child and adolescent programme. For each programme, the number of annual cohorts vaccinated was varied from 1 to 25. The outcome was defined as incremental life years gained, and the results are reported as costs per incremental life-year gained. Benefits were calculated in both undiscounted and discounted forms. All costs were discounted. The discount rate used was 6%. All major epidemiological and cost assumptions were subjected to a sensitivity analysis. Baseline results with benefits discounted range from £188 015 to £301 365 per life year gained, depending on the duration of programme and vaccination strategy. With benefits undiscounted, the comparable range is from £5234 to £13 034.
| Item Type: | Article |
|---|---|
| Official URL: | http://www.sciencedirect.com/science/journal/01634... |
| Additional Information: | © 1996 Elsevier Ltd. |
| Divisions: | Social Policy LSE Health |
| Subjects: | R Medicine > RA Public aspects of medicine |
| Date Deposited: | 06 Feb 2009 14:15 |
| Last Modified: | 11 Dec 2024 22:02 |
| URI: | http://eprints.lse.ac.uk/id/eprint/22452 |
Actions (login required)
 |
View Item |
